Samaritan Announces the Granting of European Patent for New Type of Cardiovascular Plaque Clearing Drug SP-1000

Las Vegas, NV, January 09, 2008 --(PR.com)-- Samaritan Pharmaceuticals, Inc. (OTC BB:SPHC.OB) announced today it has received a notice that a European Patent has been granted to Samaritan's SP-1000 (Cholesterol Recognition Sequence) drug for the treatment of cardiovascular disease.

The European patent is an examined document, and is enforceable as a patent after registration requirements have been fulfilled in designated countries. Samaritan is taking the appropriate steps to register the patent in the following European countries: Austria, Belgium, Switzerland/Liechtenstein, Spain, France, Great Britain, Italy, the Netherlands, and Sweden.

Previously on May 22, 2006, Samaritan announced that its collaborating scientists in two preclinical animal studies found that SP-1000 reduces blood cholesterol, clears plaque from clogged arteries, and raises HDL - the good cholesterol. For more info about SP-1000, http://www.samaritanpharma.com/cholesterol_reduction_program.asp

The patent has been awarded to Georgetown University and is exclusively licensed to Samaritan. The patent duration is 20 years from the filing date (i.e., March 12, 2019).

About Samaritan Pharmaceuticals
Samaritan focuses dually on the partnering of its promising innovative products to pharmaceutical companies; and the acquisition of the marketing and sales rights to revenue-generating marketed products for sales in Greece and Eastern Europe. This allows Samaritan to focus on its core competencies in drug discovery and drug development. Please register on the Website so the Company can notify you of upcoming conference calls, news and events.

Samaritan Pharmaceuticals: 'We LIV... to Save Lives.''

The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K/A filed November 2, 2006. The company undertakes no duty to update forward-looking statements.

Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210

Samaritan Pharmaceuticals, Inc.
Kristi Eads
702-735-7001

###